Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis

Tohoku Journal of Experimental Medicine

Volumn 222, Issue 4, 2010, Pages 319-327

  Kim, Jin Wook ^a   Lee, Sang Hyub ^a   Jeong, Sook Hyang ^a   Kim, Haeryoung ^a   Ahn, Keun Soo ^a   Cho, Jai Young ^a   Yoon, Yoo Seok ^a   Han, Ho Seong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Fbrosis; Hepatitis C virus; Lipocalin 2; Matrix metalloproteinase 9; Urine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER BIOPSY; LIVER FIBROSIS; MALE; NON INVASIVE MEASUREMENT; PROTEIN URINE LEVEL; URINALYSIS; ZYMOGRAPHY;

ACUTE-PHASE PROTEINS; CREATININE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIPOCALINS; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTO-ONCOGENE PROTEINS;

EID: 78650056123     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.222.319     Document Type: Article

References (56)

1. Bedossa, P., Dargere, D. & Paradis, V. (2003) Sampling variability of liver fbrosis in chronic hepatitis C. Hepatology, 38, 1449-1457.
2. Bedossa, P. & Poynard, T. (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24, 289-293.
3. Benyon, R.C. & Arthur, M.J. (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis., 21, 373-384.
4. Birkedal-Hansen, H., Yamada, S., Windsor, J., Pollard, A.H., Lyons, G., Stetler-Stevenson, W. & Birkedal-Hansen, B. (2008) Matrix Metalloproteinases. Curr. Protoc. Cell Biol., 40, 10.8.1-10.8.23.
5. Boeker, K.H., Haberkorn, C.I., Michels, D., Flemming, P., Manns, M.P. & Lichtinghagen, R. (2002) Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fbrosis in patients with chronic hepatitis C. Clin. Chim. Acta, 316, 71-81.
6. Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V., Campo, S., Fazio, M.R., Nicocia, G. & Buemi, M. (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol., 4, 337-344.
7. Bratt, T. (2000) Lipocalins and cancer. Biochim Biophys Acta, 1482, 318-326.
8. Bravo, A.A., Sheth, S.G. & Chopra, S. (2001) Liver biopsy. N. Engl. J. Med., 344, 495-500.
9. DeLong, E.R., DeLong, D.M. & Clarke-Pearson, D.L. (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44, 837-845.
10. Ebata, M., Fukuda, Y., Nakano, I., Katano, Y., Fujimoto, N. & Hayakawa, T. (1997) Serum levels of tissue inhibitor of metal-loproteinases-2 and of precursor form of matrix metallopro-teinase-2 in patients with liver disease. Liver, 17, 293-299.
11. Fernandez, C.A., Yan, L., Louis, G., Yang, J., Kutok, J.L. & Moses, M.A. (2005) The matrix metalloproteinase-9/neutrophil gela-tinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res., 11, 5390-5395.
12. Friedman, S.L. (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology, 134, 1655-1669.
13. Gerlach, R.F., Demacq, C., Jung, K. & Tanus-Santos, J.E. (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem., 40, 119-123.
14. Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B. (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49, 1335-1374.
15. Gressner, A.M., Gao, C.F. & Gressner, O.A. (2009) Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J. Gastroenterol., 15, 2433-2440.
16. Han, Y.P. (2006) Matrix metalloproteinases, the pros and cons, in liver fbrosis. J. Gastroenterol. Hepatol., 21 Suppl 3, S88-91.
17. Han, Y.P., Yan, C., Zhou, L., Qin, L. & Tsukamoto, H. (2007) A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J. Biol. Chem., 282, 12928-12939.
18. Han, Y.P., Zhou, L., Wang, J., Xiong, S., Garner, W.L., French, S.W. & Tsukamoto, H. (2004) Essential role of matrix metallopro-teinases in interleukin-1-induced myofbroblastic activation of hepatic stellate cell in collagen. J. Biol. Chem., 279, 4820-4828.
19. Hayasaka, A., Suzuki, N., Fujimoto, N., Iwama, S., Fukuyama, E., Kanda, Y. & Saisho, H. (1996) Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelati- nase B) in hepatocellular carcinoma. Hepatology, 24, 1058-1062.
20. Imbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y. & Poynard, T. (2001) Biochemical markers of liver fbrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 357, 1069-1075.
21. Iredale, J.P. (2007) Models of liver fbrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest., 117, 539-548.
22. Jung, K., Lein, M., Laube, C. & Lichtinghagen, R. (2001) Blood specimen collection methods infuence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta, 314, 241-244.
23. Jung, K., Lein, M., Roemer, A. & Lichtinghagen, R. (2002) Circulating gelatinase B (MMP-9)-the impact of the preanalytical step of blood collection. Matrix Biol., 21, 381-382.
24. Kim, J.W., Lee, S.H., Park, Y.S., Jeong, S.H., Kim, N., Lee, D.H. & Lee, H.S. (2009) Transcriptome analysis of hepatitis B virus-associated small hepatocellular carcinoma by serial analysis of gene expression. Int. J. Oncol., 35, 129-137.
25. Kjeldsen, L., Johnsen, A.H., Sengelov, H. & Borregaard, N. (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem., 268, 10425-10432.
26. Kossakowska, A.E., Edwards, D.R., Lee, S.S., Urbanski, L.S., Stabbler, A.L., Zhang, C.L., Phillips, B.W., Zhang, Y. & Urbanski, S.J. (1998) Altered balance between matrix metal-loproteinases and their inhibitors in experimental biliary fbrosis. Am. J. Pathol., 153, 1895-1902.
27. Kuo, W.H., Chou, F.P., Lu, S.C., Chu, S.C. & Hsieh, Y.S. (2000) Signifcant differences in serum activities of matrix metallo-proteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Clin. Chim. Acta, 294, 157-168.
28. Leber, T.M. & Balkwill, F.R. (1997) Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem., 249, 24-28.
29. Leroy, V., Monier, F., Bottari, S., Trocme, C., Sturm, N., Hilleret, M.N., Morel, F. & Zarski, J.P. (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol., 99, 271-279.
30. Lichtinghagen, R., Bahr, M.J., Wehmeier, M., Michels, D., Haberkorn, C.I., Arndt, B., Flemming, P., Manns, M.P. & Boeker, K.H. (2003) Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin. Sci. (Lond), 105, 373-382.
31. Lichtinghagen, R., Huegel, O., Seifert, T., Haberkorn, C.I., Michels, D., Flemming, P., Bahr, M. & Boeker, K.H. (2000) Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin. Chem., 46, 183-192.
32. Lichtinghagen, R., Michels, D., Haberkorn, C.I., Arndt, B., Bahr, M., Flemming, P., Manns, M.P. & Boeker, K.H. (2001) Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fbroproliferative process in the liver during chronic hepatitis C. J. Hepatol., 34, 239-247.
33. Manning, D.S. & Afdhal, N.H. (2008) Diagnosis and quantitation of fbrosis. Gastroenterology, 134, 1670-1681.
34. McHutchison, J.G., Blatt, L.M., de Medina, M., Craig, J.R., Conrad, A., Schiff, E.R. & Tong, M.J. (2000) Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol., 15, 945-951.
35. Mehta, P., Ploutz-Snyder, R., Nandi, J., Rawlins, S.R., Sanderson, S.O. & Levine, R.A. (2008) Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fbrosis stages in chronic hepatitis C. Am. J. Gastroen-terol., 103, 928-936.
36. Milani, S., Herbst, H., Schuppan, D., Grappone, C., Pellegrini, G., Pinzani, M., Casini, A., Calabro, A., Ciancio, G., Stefanini, F., Ciancio, A.K. & Surrenti, C. (1994) Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fbrotic human liver. Am. J. Pathol., 144, 528-537.
37. Mishra, J., Ma, Q., Kelly, C., Mitsnefes, M., Mori, K., Barasch, J. & Devarajan, P. (2006) Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr. Nephrol., 21, 856-863.
38. Mishra, J., Mori, K., Ma, Q., Kelly, C., Yang, J., Mitsnefes, M., Barasch, J. & Devarajan, P. (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol., 15, 3073-3082.
39. Moses, M.A., Wiederschain, D., Loughlin, K.R., Zurakowski, D., Lamb, C.C. & Freeman, M.R. (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res., 58, 1395-1399.
40. Murawaki, Y., Koda, M., Okamoto, K., Mimura, K. & Kawasaki, H. (2001) Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fbrotic stage in patients with chronic hepatitis C. J. Gastroenterol. Hepatol.,16, 777-781.
41. Nunez, O., Fernandez-Martinez, A., Majano, P.L., Apolinario, A., Gomez-Gonzalo, M., Benedicto, I., Lopez-Cabrera, M., Bosca, L., Clemente, G., Garcia-Monzon, C. & Martin-Sanz, P. (2004) Increased intrahepatic cyclooxygenase 2, matrix metallopro-teinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut, 53, 1665-1672.
42. Reif, S., Aeed, H., Shilo, Y., Reich, R., Kloog, Y., Kweon, Y.O. & Bruck, R. (2004) Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J. Hepatol., 41, 235-241.
43. Reif, S., Somech, R., Brazovski, E., Reich, R., Belson, A., Konikoff, F.M. & Kessler, A. (2005) Matrix metalloprotein-ases 2 and 9 are markers of infammation but not of the degree of fbrosis in chronic hepatitis C. Digestion, 71, 124-130.
44. Roy, R., Louis, G., Loughlin, K.R., Wiederschain, D., Kilroy, S.M., Lamb, C.C., Zurakowski, D. & Moses, M.A. (2008) Tumor-specifc urinary matrix metalloproteinase fngerprinting: iden-tifcation of high molecular weight urinary matrix metallopro-teinase species. Clin. Cancer Res., 14, 6610-6617.
45. Smyth, R., Lane, C.S., Ashiq, R., Turton, J.A., Clarke, C.J., Dare, T.O., York, M.J., Griffiths, W. & Munday, M.R. (2009) Proteomic investigation of urinary markers of carbon-tetra-chloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol. Toxicol., 25, 499-512.
46. Takahara, T., Zhang, L.P., Yata, Y., Xue, F., Minemura, M., Sato, H. & Watanabe, A. (2003) Modulation of matrix metallopro-teinase-9 in hepatic stellate cells by three-dimensional type I collagen: its activation and signaling pathway. Hepatol. Res., 26, 318-326.
47. Takahara, Y., Takahashi, M., Wagatsuma, H., Yokoya, F., Zhang, Q.W., Yamaguchi, M., Aburatani, H. & Kawada, N. (2006) Gene expression profles of hepatic cell-type specifc marker genes in progression of liver fbrosis. World J. Gastroenterol., 12, 6473-6499.
48. Trevisan, A. (1990) Concentration adjustment of spot samples in analysis of urinary xenobiotic metabolites. Am. J. Ind. Med., 17, 637-642.
49. Trocme, C., Leroy, V., Sturm, N., Hilleret, M.N., Bottari, S., Morel, F. & Zarski, J.P. (2006) Longitudinal evaluation of a fbrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J. Viral Hepat., 13, 643-651.
50. Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfeisch, J.D., Marrero, J.A., Conjeevaram, H.S. & Lok, A.S. (2003) A simple nonin-vasive index can predict both signifcant fbrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38, 518-526.
51. Walsh, K.M., Fletcher, A., MacSween, R.N. & Morris, A.J. (2000) Basement membrane peptides as markers of liver disease in chronic hepatitis C. J. Hepatol., 32, 325-330.
52. Walsh, K.M., Timms, P., Campbell, S., MacSween, R.N. & Morris, A.J. (1999) Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig. Dis. Sci., 44, 624-630.
53. Woitas, R.P., Heller, J., Stoffel-Wagner, B., Spengler, U. & Sauerbruch, T. (1997) Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepa-tology, 26, 858-864.
54. Wong, F., Massie, D., Colman, J. & Dudley, F. (1993) Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology, 104, 884-889.
55. Xu, S. & Venge, P. (2000) Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta, 1482, 298-307.
56. Yan, L., Borregaard, N., Kjeldsen, L. & Moses, M.A. (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem., 276, 37258-37265.